pharmaceutical daily

BMS builds new cell therapy manufacturing facility in the Netherlands

Bristol Myers Squibb has selected Leiden, Netherlands to house a new cell therapy manufacturing site in Europe, leveraging the growing life sciences region near Amsterdam and convenient access to transportation for shipping patient cells.
Bristol Myers Squibb is making this investment to expand global manufacturing capacity and bring treatments to patients faster, the company said.

Leiden will be the company’s fifth cell therapy manufacturing facility and first in Europe.

Ann Lee, Ph.D., Senior Vice President, Cell Therapy Development & Operations, Bristol Myers Squibb said: “We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey.”

The company noted that the European facility will be commercially focused with capabilities for multi-product cell therapy manufacturing and the ability to scale up capacity. It will leverage innovative technologies, the latest manufacturing equipment and advanced digital systems to deliver these critical cell therapies to patients.

Planning for site design and development is underway, with construction slated to begin later this year, BMS said.

Exit mobile version